Drug Type Small molecule drug |
Synonyms Belnacasan (USAN) |
Target |
Mechanism caspase 1 inhibitors(Caspase-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H33ClN4O6 |
InChIKeySJDDOCKBXFJEJB-MOKWFATOSA-N |
CAS Registry273404-37-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10416 | Belnacasan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 1 | DE | 01 Dec 2011 | |
Epilepsies, Partial | Phase 1 | US | 01 Jan 2010 | |
Peritoneal Fibrosis | Preclinical | JP | 13 Jun 2019 | |
Plaque psoriasis | Preclinical | - | 01 Dec 2004 |
Phase 2 | 40 | (Interventional) | jxbqyggxpw(pwotvfmmte) = fapuloupkd bvpjkahzqa (fymulejzce, erjtuueqgo - apmegyrohx) View more | - | 19 Sep 2024 | ||
Placebo (Placebo) | jxbqyggxpw(pwotvfmmte) = ogteobkoef bvpjkahzqa (fymulejzce, lygztatuck - fddtffskkw) View more | ||||||
Phase 2 | Epilepsy interleukin 1 beta (IL-1β) | 48 | qdrqgjicxb(alyuedlnyp) = acrbhbvqez blcmoipmpb (sfoxlcwouh ) | Positive | 12 Feb 2013 |